Aptevo Therapeutics Augments Leadership Team
Appoints Former GlaxoSmithKline Executive
Senior Vice President, Operations
“We are delighted to welcome Randy to the executive leadership team at Aptevo,” said
In his new role at Aptevo, Mr. Maddux will work closely with the research, clinical and regulatory organizations to set strategic direction and provide operational support for the development of novel bispecific antibody candidates derived from Aptevo’s proprietary ADAPTIR™ platform. He will also provide oversight and direction in support of the supply chain for the Company’s four commercial products – IXINITY®, WINRHO®, HEPAGAM B® and VARIZIG®.
Prior to joining Aptevo, Mr. Maddux served as Vice President and Site Director at GlaxoSmithKline, where he led the largest biopharmaceutical development and manufacturing site within the GSK manufacturing network. Before that, Mr. Maddux served as Vice President of Manufacturing Operations at Human Genome Sciences, where he held executive responsibility for all activities associated with the manufacture of therapeutic proteins. Prior to joining Human Genome Sciences, Mr. Maddux held various leadership roles in operations and quality at Biogen and Glaxo. Mr. Maddux holds a M.B.A. from
Mr. White continued, “We are also pleased to announce the promotion of
Dr. Gross has a Ph.D. in immunology and over twenty-five years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease and oncology indications. Prior to joining Emergent, Dr. Gross served as Vice President of
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding the potential opportunities and financial impact of the transaction, our technology and related pipeline, collaboration and partnership opportunities and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; adverse developments in our customer-base or markets; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the
Aptevo Therapeutics Stacey JurchisonSenior Director, Investor Relations and Corporate Communications 206-859-6628 JurchisonS@apvo.com